Estimation of Control Modulated by Dopamine in Parkinson's Disease Filip Grill^{1,2}, Romain Ligneul³, CONTROL-PD, *Rick Helmich^{1,2} & *Roshan Cools^{1,4}

¹Donders Institute, Radboud University, Nijmegen, The Netherlands; ²Department of Neurology, Radboud UMC, Nijmegen, The Netherlands; ³Lyon Neuroscience Research Centre, Lyon, France; ⁴Department of Psychiatry, Radboud UMC, Nijmegen, The Netherlands; ³Lyon Neuroscience Research Centre, Lyon, France; ⁴Department of Psychiatry, Radboud UMC, Nijmegen, The Netherlands; ³Lyon Neuroscience Research Centre, Lyon, France; ⁴Department of Psychiatry, Radboud UMC, Nijmegen, The Netherlands; ³Lyon Neuroscience Research Centre, Lyon, France; ⁴Department of Psychiatry, Radboud UMC, Nijmegen, The Netherlands; ³Lyon Neuroscience Research Centre, Lyon, France; ⁴Department of Psychiatry, Radboud UMC, Nijmegen, The Netherlands; ³Lyon Neuroscience Research Centre, Lyon, France; ⁴Department of Psychiatry, Radboud UMC, Nijmegen, The Netherlands; ³Lyon Neuroscience Research Centre, Lyon, France; ⁴Department of Psychiatry, Radboud UMC, Nijmegen, The Netherlands; ³Lyon Neuroscience Research Centre, Lyon, France; ⁴Department of Psychiatry, Radboud UMC, Nijmegen, The Netherlands; ³Lyon Neuroscience Research Centre, Lyon, France; ⁴Department of Psychiatry, Radboud UMC, Nijmegen, The Netherlands; ³Lyon Neuroscience Research Centre, Lyon, France; ⁴Department of Psychiatry, Radboud UMC, Nijmegen, The Netherlands; ³Lyon Neuroscience Research Centre, Lyon, France; ⁴Department of Psychiatry, Radboud UMC, Nijmegen, The Netherlands; ³Lyon Neuroscience Research Centre, Lyon, France; ⁴Department of Psychiatry, Radboud UMC, Nijmegen, The Netherlands; ³Lyon Neuroscience Research Centre, Lyon, France; ⁴Department of Psychiatry, Radboud UMC, Nijmegen, The Netherlands; ³Lyon Neuroscience Research Centre, Lyon, France; ⁴Department of Psychiatry, Radboud UMC, Nijmegen, The Netherlands; ³Lyon Neuroscience Research Centre, Lyon, France; ⁴Department of Psychiatry, Radboud UMC, Nijmegen, The Netherlands; ³Lyon Neuroscience Research Centre, Lyon, Separtment of Netherlands; ⁴Department of Nether

INTRODUCTION

Depression is highly prevalent in Parkinson's disease (PD)¹

• Aberrant dopamine signaling is a factor impairing the ability to learn statistical regularities in the environment^{2,3,4}

• Estimating the controllability of the environment is a key environmental statistic fundamental to the learned helplessness model of depression⁵

• We hypothesize that dopamine plays a crucial role in estimating the controllability of the environment • Does dopamine signaling affect the estimation of environmental controllability in persons with PD?

• We conducted an **online study with 90 individuals** diagnosed with PD



• Perform a task designed to assess their ability to estimate the controllability of the environment⁶ Prior to the task participants were asked to self-report how medicated they felt

The influence actions have over the environment

TASK

• On each trial, participants see 1 of 3 states (island, lighthouse, harbor) and are instructed to predict the state on the next trial.

- They are told that the next state can depend on which boat they choose (in controllable task-phases) or only on which state they are in now (in uncontrollable task-phases). To predict the next state, they need to choose between boats to find out whether they are in a controllable or uncontrollable phase.



RESULTS

Higher subjective medication state is associated with higher controllability estimates, leading to higher accuracy of controllability estimates in controllable task-phases, but lower accuracy of controllability estimates in uncontrollable task-phases.



Interaction between subjective medication state and accuracy

CONCLUSIONS -

• The current results show an interaction between environmental controllability estimation and dopaminergic function. This suggests that there is a potential link between dopamine and the estimation of control in PD.

• This work may offer insight into the mechanisms underlying psychiatric symptoms like **depression** in PD and provide potential avenue for refining therapeutic approaches that target cognitive aspect of the disease.

• We are continuously collecting more data on this task from cohorts involved in the CONTROL-PD consortium.

REFERENCES

- 1. Reijnders, J. S. A. M., Ehrt, U., Weber, W. E. J., Aarsland, D., & Leentjens, A. F. G. (2008). A systematic review of prevalence studies of depression in Parkinson's disease. Movement Disorders, 23(2), 183–189. https://doi.org/10.1002/mds.21803
- 2. Schultz, W., Dayan, P., & Montague, P. R. (1997). A neural substrate of prediction and reward. Science, 275(5306), 1593–1599. https://doi.org/10.1126/science.275.5306.159
- 3. Robbins, T. W., & Everitt, B. J. (2007). A role for mesencephalic dopamine in activation: Commentary on Berridge (2006). Psychopharmacology, 191(3), 433–437. https://doi.org/10.1007/s00213-006-0528-7
- 4. Gershman, S. J., & Uchida, N. (2019). Believing in dopamine. Nature Reviews Neuroscience, 20(November), 703–714. https://doi.org/10.1038/s41583-019-0220-7
- 5. Maier, S. F., & Seligman, M. E. P. (2016). Learned helplessness at fifty: Insights from neuroscience. Psychological Review, 123(4), 349–367. https://doi.org/10.1037/rev0000033
- 6. Ligneul, R., Mainen, Z. F., Ly, V., & Cools, R. (2022). Stress-sensitive inference of task controllability. Nature Human Behaviour, 6(6), 812–822. https:// doi.org/10.1038/s41562-022-01306-w

• Further research is required to confirm these preliminary findings and explore the underlying neural mechanisms in more detail. To identify the specific mechanism being modulated by dopamine a **computational model** needs to be fit to the data.

